Integra LifeSciences (NASDAQ:IART) Stock Price Target Lowered at Truist Financial

Key Points

Error: Response status code does not indicate success: 500 (Internal Server Error).

Integra LifeSciences (NASDAQ:IART - Get Free Report) had its price target reduced by equities research analysts at Truist Financial from $19.00 to $15.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a "hold" rating on the life sciences company's stock. Truist Financial's target price suggests a potential upside of 15.19% from the company's current price.

A number of other brokerages have also recently issued reports on IART. Wall Street Zen cut shares of Integra LifeSciences from a "buy" rating to a "hold" rating in a report on Saturday, October 3rd. Citigroup reissued a "neutral" rating and set a $15.00 price target (down from $19.00) on shares of Integra LifeSciences in a research note on Monday, October 5th. Wells Fargo & Company set a $15.00 price target on Integra LifeSciences in a research note on Saturday, October 3rd. BMO Capital Markets lowered their price target on Integra LifeSciences from $18.00 to $15.00 and set a "market perform" rating on the stock in a report on Monday, October 5th. Finally, Weiss Ratings downgraded Integra LifeSciences from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Friday, October 2nd. One equities research analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Reduce" and a consensus price target of $16.71.

Integra LifeSciences Stock Down 6.0%

NASDAQ:IART traded down $0.83 during trading hours on Wednesday, hitting $13.02. The company's stock had a trading volume of 344,372 shares, compared to its average volume of 900,237. The company has a current ratio of 3.60, a quick ratio of 2.11 and a debt-to-equity ratio of 1.75. Integra LifeSciences has a 52-week low of $8.70 and a 52-week high of $20.49. The stock has a market capitalization of $1.01 billion, a P/E ratio of -144.81, a price-to-earnings-growth ratio of 0.72 and a beta of 1.21. The stock has a fifty day moving average of $16.07 and a 200-day moving average of $15.40.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.08. The company had revenue of $418.76 million during the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. On average, equities analysts forecast that Integra LifeSciences will post 2.47 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio acquired a new position in Integra LifeSciences during the second quarter worth approximately $82,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Integra LifeSciences during the 2nd quarter worth $84,000. Sequoia Financial Advisors LLC increased its holdings in shares of Integra LifeSciences by 27.4% during the 1st quarter. Sequoia Financial Advisors LLC now owns 14,233 shares of the life sciences company's stock worth $134,000 after buying an additional 3,059 shares during the last quarter. Amundi increased its holdings in shares of Integra LifeSciences by 80.8% during the 1st quarter. Amundi now owns 19,430 shares of the life sciences company's stock worth $183,000 after buying an additional 8,681 shares during the last quarter. Finally, Corient Private Wealth LP raised its position in shares of Integra LifeSciences by 66.9% in the 2nd quarter. Corient Private Wealth LP now owns 22,749 shares of the life sciences company's stock worth $409,000 after buying an additional 9,120 shares during the period. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation NASDAQ: IART is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.

The company's products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.